FDA-cleared profile

MammoScreen BD

Therapixel · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.

Clinical role
Breast-density assessment support
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Adjunctive information only; not diagnostic, and patient-management decisions should not be made solely from MammoScreen BD.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.
  • Who uses it?Intended users: Physicians interpreting mammograms, including radiologists
  • What does the software produce?Output: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
  • What is its most important limitation?Key limitation: Adjunctive information only; not diagnostic, and patient-management decisions should not be made solely from MammoScreen BD.

Clinical takeaway. Clinical role: MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.

Evidence takeaway. Evidence from the reviewed source record: Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
MammoScreen BD evaluates 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or 2D synthetic mammography from DBT to assign an ACR BI-RADS 5th Edition breast-density category for asymptomatic women aged 40 years or older undergoing screening; it is adjunctive, not diagnostic, and patient management remains with the interpreting physician.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Breast-density assessment support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult screening mammography; asymptomatic women aged 40 years or older
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Physicians interpreting mammograms, including radiologists
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
Adjunctive information only; not diagnostic, and patient-management decisions should not be made solely from MammoScreen BD.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone clinical validation compared MammoScreen BD density categories with consensus from five breast radiologists; the FDA packet describes validation across compatible FFDM and DBT inputs.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

MammoScreen BD breast-density clinical validation

  • DesignStandalone clinical validation against consensus reference
  • PopulationAsymptomatic women aged 40 years or older undergoing screening mammography on compatible FFDM and DBT systems
  • Scopeexact submission
  • Tested versionMammoScreen BD submitted in K243685; build not stated
  • IndependenceIndependence not established

K243685

Reference standard was the consensus of five breast radiologists; exact enrollment count was not used here because it was not consistently exposed in the extracted packet text.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
MammoScreen family SaaS priced per successfully processed mammogram; the official FAQ also states that version updates are automatic.
  • Product family
  • Checked 2026-09-07

The reviewed FAQ does not publish an exact amount, currency, geography, or contract term. Cloud de-identification/deletion statements were not treated as a scoped security audit.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 2D mammography standard views (CC and/or MLO) from compatible FFDM and/or DBT systems using 2D synthetic mammography; the FDA labeling describes Hologic and GE compatible systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K243685: MammoScreen BD

  2. Routing

    Source context, not route validation: The FDA submission describes DICOM input and JSON output, with optional DICOM SR, DICOM Secondary Capture, and worklist display through third-party software; local interface compatibility remains site-specific.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K243685: MammoScreen BD

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 ·

  4. Returned objects

    Source context, not route validation: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K243685: MammoScreen BD

  5. Viewer/worklist/report

    Unresolved route: A breast-density category of A, B, C, or D; output is provided as JSON and can be displayed as a DICOM Structured Report, DICOM Secondary Capture Image, or in patient worklists through compatible third-party software.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K243685: MammoScreen BD

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA submission describes DICOM input and JSON output, with optional DICOM SR, DICOM Secondary Capture, and worklist display through third-party software; local interface compatibility remains site-specific.
  • Exact FDA submission
  • Checked 2026-09-06
Security
Therapixel's own page says Therapixel and its operations for MammoScreen are ISO/IEC 27001 certified by an independent certification body. The page gives no certificate number, scope statement, issue date or expiry, and the certificate was not read.
  • Vendor-wide
  • Checked 2026-10-25

Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.

DICOM and JSON result pathways

The exact submission describes DICOM mammography input and JSON output, with optional DICOM Structured Report, Secondary Capture, and compatible worklist display.

exact submission · checked 2026-09-06

Family pricing model

MammoScreen's official FAQ describes SaaS pricing on a pay-per-successfully-processed-mammogram basis; no amount or contract term is published.

product family · checked 2026-09-07

Family-level commercial model only; it is not treated as a price for the K243685 configuration.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243685
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-08-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
23Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, vendor faq, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Therapixel MammoScreen reimbursement CPT coverage"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. Therapixel's adoption page describes general US screening mammography policy; it states no coding or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.

  • Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission

    The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

9 sources - 3 history items

Source ledger

  1. FDA 510(k) K243685: MammoScreen BD

    U.S. Food and Drug Administration - Published 2025-08-22 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. MammoScreen BD model card (K243685)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. MammoScreen official product page

    Therapixel - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

  8. MammoScreen official FAQ

    Therapixel - Accessed 2026-09-07

    Scope: pricingModel, implementationCapabilities

  9. Therapixel is now ISO/IEC 27001 certified

    Therapixel - Accessed 2026-10-25

    Scope: security

Research history

  1. K243685 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history